Polymyxin Triple Combinations against Polymyxin-Resistant, Multidrug-Resistant, KPC-Producing Klebsiella pneumoniae-Reference-Cited by-同舟云学术

Polymyxin Triple Combinations against Polymyxin-Resistant, Multidrug-Resistant, KPC-Producing Klebsiella pneumoniae

Published:2020-07-22 Issue:8 Volume:64 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Aye Su Mon¹,Galani Irene²,Yu Heidi¹,Wang Jiping¹,Chen Ke¹,Wickremasinghe Hasini¹,Karaiskos Ilias³,Bergen Phillip J.¹,Zhao Jinxin¹,Velkov Tony⁴,Giamarellou Helen³,Lin Yu-Wei¹,Tsuji Brian T.⁵,Li Jian¹

Affiliation:

1. Monash Biomedicine Discovery Institute, Department of Microbiology, Monash University, Clayton, Victoria, Australia

2. Fourth Department of Internal Medicine, National and Kapodistrian University of Athens, Athens, Greece

3. First Department of Internal Medicine-Infectious Diseases, Hygeia General Hospital, Athens, Greece

4. Department of Pharmacology & Therapeutics, School of Biomedical Sciences, Faculty of Medicine, Dentistry and Health Sciences, The University of Melbourne, Parkville, Victoria, Australia

5. Laboratory for Antimicrobial Pharmacodynamics, NYS Centre of Excellence in Bioinformatics & Life Sciences, Buffalo, New York, USA

Abstract

Resistance to polymyxin antibiotics is increasing. Without new antibiotic classes, combination therapy is often required. We systematically investigated bacterial killing with polymyxin-based combinations against multidrug-resistant (including polymyxin-resistant), carbapenemase-producing Klebsiella pneumoniae . Monotherapies and double- and triple-combination therapies were compared to identify the most efficacious treatment using static time-kill studies (24 h, six isolates), an in vitro pharmacokinetic/pharmacodynamic model (IVM; 48 h, two isolates), and the mouse thigh infection model (24 h, six isolates).

Funder

HHS | National Institutes of Health

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.00246-20

Reference75 articles.

1. Carbapenemase-Producing Klebsiella pneumoniae, a Key Pathogen Set for Global Nosocomial Dominance

2. Klebsiella: a long way to go towards understanding this enigmatic jet-setter

3. Centers for Disease Control and Prevention (CDC). 2019. Antibiotic resistance threats in the United States 2019. CDC Atlanta GA. https://www.cdc.gov/drugresistance/pdf/threats-report/2019-ar-threats-report-508.pdf.

4. Klebsiella pneumoniae: a major worldwide source and shuttle for antibiotic resistance

5. Circumventing resistance to anti-infective agents

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Promising treatments for refractory pneumonia caused by multidrug-resistant Klebsiella pneumoniae;Journal of Drug Delivery Science and Technology;2023-09

2. Glucose Induces Resistance to Polymyxins in High-Alcohol-Producing Klebsiella pneumoniae via Increasing Capsular Polysaccharide and Maintaining Intracellular ATP;Microbiology Spectrum;2023-08-17

3. Antibiotic Susceptibility, Biofilm-Forming Ability, and Prevalence of Extended-Spectrum Beta-Lactamase (ESBL)- and Biofilm-Associated Genes Among Klebsiella pneumoniae Isolates from Hospitalized Patients in Northwest of Iran;Current Microbiology;2023-04-08

4. Proof‐of‐concept for incorporating mechanistic insights from multi‐omics analyses of polymyxin B in combination with chloramphenicol against Klebsiella pneumoniae;CPT: Pharmacometrics & Systems Pharmacology;2023-02

5. Macrolide, lincosamide, glycopeptide, and other antibacterial antibiotics;Medicinal Chemistry of Chemotherapeutic Agents;2023